Document Detail


Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives.
MedLine Citation:
PMID:  17956203     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Aliskiren, the direct renin inhibitor, is the first new class of drug available in 13 years for the treatment of hypertension. Renin has long been recognized as a preferred site for blockade of the renin-angiotensin-aldosterone system because it prevents conversion of angiotensinogen to angiotensin I. Aliskiren binds to the active site of the renin molecule, blocking angiotensinogen cleavage, thus, preventing the formation of angiotensin I. Clinical studies have demonstrated at least equivalent or superior blood pressure lowering efficacy compared with existing drugs with a favorable side effect profile. Aliskiren possesses possible synergistic potential when combined with a thiazide diuretic, ACE inhibitor, angiotensin receptor blocker and calcium channel blocker both in terms of efficacy and tolerability. This review aims to define the role of aliskiren in the therapeutic management of hypertension.
Authors:
Byung-Hee Oh
Related Documents :
6253243 - Enhancement by diuretics of the antihypertensive action of long-term angiotensin conver...
2541403 - Resetting of pressure-dependent renin release by intrarenal alpha 1-adrenoceptors in co...
9146803 - Effects of rotational myocardial anisotropy in forward potential computations with equi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  8     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-10-24     Completed Date:  2007-11-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2839-49     Citation Subset:  IM    
Affiliation:
Seoul National University College of Medicine, Department of Internal Medicine, 28 Yongon-dong, Jongno-gu, Seoul, 110-744, Korea. ohbhmed@snu.ac.kr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amides / adverse effects,  chemistry,  pharmacokinetics,  therapeutic use*
Animals
Antihypertensive Agents / adverse effects,  chemistry,  pharmacokinetics,  therapeutic use*
Fumarates / adverse effects,  chemistry,  pharmacokinetics,  therapeutic use*
Humans
Hypertension / drug therapy*
Renin / antagonists & inhibitors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Amides; 0/Antihypertensive Agents; 0/Fumarates; 0/aliskiren; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Drug evaluation of clopidogrel in patients with ischemic stroke.
Next Document:  Capecitabine in advanced gastric cancer.